Table 1 Basic information of the included studies
Author (years) | Country | Research period | Study type | Meidian follow-up(months) | Sample size | Median age (W1,W3, y) | Sex(W1:M/F; W3:M/F) | Clinical stage | ECOG or KPS | Assessment of toxicity | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
T | W1 | W3 | ||||||||||
Zhu 2018 | China | 2010–2013 | Re | W1:51 W3:50 | 859 | 225 | 634 | W1:45.2 W3:45 | W1:170/55 W3:475/159 | III–IVb (UICC 7th) | 70–100 | CTCAE 4.0 |
Xia 2021 | China | 2011–2016 | RCT | 58.3 | 510 | 250 | 260 | W1:43 W3:44.5 | W1:180/70 W3:177/83 | III–IVb (AJCC 7th) | 70–100 | CTCAE 4.0 |
Wang 2019 | China | 2010–2013 | Re | 60.2 | 322 | 93 | 229 | NA | W1:83/10 W3:217/12 | I–Iva (AJCC 8th) | NA | CTCAE 4.0 |
Meng 2018 | China | 2008–2011 | Re | 69 | 180 | 90 | 90 | W1:46 W3:41 | W1:57/33 W3:57/33 | III–IVb (AJCC 7th) | 80–100 | CTCAE 3.0 |
Lee 2015 | Korea | 2009–2013 | RCT | 30 | 109 | 53 | 56 | W1:53.6 W3:52.7 | W1:39/14 W3:47/9 | II–IVb (AJCC 5th) | 0–2 | NA |
Jagdis 2014 | Canada | 2000–2009 | Re | W1:36 W3:72 | 73 | 45 | 28 | W1:51 W3:49.5 | W1:35/10 W3:15/13 | II–IVb (UICC 7th) | 0–3 | CTCAE 3.0 |
Gundog2019 | Turkey | 2010–2018 | Re | 41.5 | 98 | 61 | 37 | NA | W1:45/16 W3:25/12 | II–Iva (AJCC 8th) | 70–100 | CTCAE 3.0 |